Premium
Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain‐Barré syndrome
Author(s) -
Dujmovic Irena,
Lunn Michael P.,
Reilly Mary M.,
Petzold Axel
Publication year - 2013
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.23752
Subject(s) - cerebrospinal fluid , guillain barre syndrome , biomarker , neurofilament , medicine , pathology , axonal degeneration , immunology , immunohistochemistry , biology , biochemistry
Proximal axonotmesis results in the release of neurofilament (Nf) proteins into the cerebrospinal fluid (CSF) in patients with Guillain‐Barré syndrome (GBS). High CSF levels of the phosphorylated form of Nf‐heavy chain (NfH SMI35 ) at GBS onset have been reported to be a poor prognostic marker, but routine measurement of CSF NfH SMI35 levels has not been done and the longitudinal profile of CSF NfH SMI35 levels in GBS is not known. Methods This prospective case series describes the clinical, neurophysiological, and biomarker characteristics of 3 patients with severe GBS. Results High and increasing levels of CSF NfH SMI35 in serial CSF samples were associated with poor clinical and electrophysiological outcome. Conclusions These data further suggest that CSF NfH SMI35 could be a prognostic biomarker which might indicate the development of retrograde axonal degeneration or additional proximal axonal damage during the course of GBS. Muscle Nerve , 2013